Inventiva S.A. American Depository Shares (IVA) vs SpyGlass Pharma (SGP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
SpyGlass Pharma is the larger company by market cap ($813.1 million vs $790.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IVA | SGP |
|---|---|---|
| Share price | $3.35 | $24.31 |
| Market cap | $790.16M | $813.12M |
| 1-day change | -0.59% | +1.72% |
| YTD return | -27.63% | — |
| 1-year return | -39.04% | — |
| 5-year return | -74.89% | — |
| EPS (TTM) | $-0.62 | $-2.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.98 | $32.44 |
| 52-week low | $3.11 | $17.06 |
| Distance from 52-week high | -58.10% | -25.06% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +354.41% | +81.00% |
| Average volume | 1.38M | 111.13K |
| Shares outstanding | 236.22M | 33.45M |
| Employees | 87 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Inventiva S.A. American Depository Shares
IVA stock →Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
About SpyGlass Pharma
SGP stock →SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions.
Health Care · Medical/Dental Instruments · 76 employees
IVA vs SGP FAQ
Which is bigger, Inventiva S.A. American Depository Shares or SpyGlass Pharma?
SpyGlass Pharma (SGP) is larger, with a market capitalization of $813.12M compared with $790.16M for Inventiva S.A. American Depository Shares (IVA).
Are Inventiva S.A. American Depository Shares and SpyGlass Pharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Inventiva S.A. American Depository Shares and Medical/Dental Instruments for SpyGlass Pharma.